What KEDPlasma does

KEDPlasma is the U.S. plasma-collection subsidiary of Italian biopharma group Kedrion Biopharma, operating 70+ company-owned plasma donation centers across 20+ U.S. states plus 5 centers in the Czech Republic. Founded in 2004 and significantly expanded in 2022 through the integration of UK-based BPL Plasma's 29 U.S. centers, KEDPlasma collects source and specialty human plasma via plasmapheresis — separating plasma by centrifugation and returning red cells to the donor — for processing into Kedrion's portfolio of 37 plasma-derived medicinal products (albumin, clotting factors, immunoglobulins) distributed to rare-disease patients in 100+ countries.

The business operates a community-led, donor-incentivized model: individual donors receive per-donation monetary compensation (typically $30–$50 range, varying by center and specialty) and are retained through the KEDLeague tiered loyalty program (Bronze/Silver/Gold/Platinum), the KEDPLASMA Donor App (iOS/Android) with earnings planning and vitals tracking, and the KEDExpress online health questionnaire portal. A biometric donor identification system from Haemonetics authenticates repeat donors and supports regulatory compliance. KEDPlasma differentiates itself through 10 specialty plasma programs — Anti-D, Tetanus, Anti-smallpox (VIG), Anti-hepatitis B, Anthrax (vaccinated and non-vaccinated), Rabies, Viral Inactivation, CMV, and Anti-varicella zoster — serving both commercial therapy demand and U.S. strategic national stockpile requirements. A 2023 nationwide remodeling initiative, executed with Stough Development Corporation, is consolidating all centers under a unified KEDPlasma brand with modernized facilities.

Name

KEDPlasma

Legal name

Kedrion Biopharma

Website

https://kedplasma.us

Company type

Private

Founded year

2004

Operating status

Operating

Headcount range

101–250 employees

Short description

KEDPlasma is the U.S. plasma-collection subsidiary of Kedrion Biopharma, operating 70+ donation centers across 20+ states that supply source and specialty plasma (including Anti-D, Rabies, and Anthrax) for processing into plasma-derived therapies for rare-disease patients worldwide.

Ownership category

akta.pro rank

Product category

Plasma Collection Services

NAICS

Blood and Organ Banks (621991)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Plasma Collection & Donor Services (Plasmapheresis Centers) (HLAIAHAH)

akta.pro secondary industries

Plasma Fractionation & Purification Manufacturing (HLAIAHAI), Plasma-Derived Therapy Quality, Safety & Pharmacovigilance (Pathogen Reduction/Testing) (HLAIAHAK)

Keywords

• Plasma collection services
• Plasma donation centers
• Specialty plasma programs
• Donor compensation programs
• Plasma-derived therapies

Headquarters

HQ city

Atlanta

HQ country

United States

HQ region

North America

Offices69 records

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Supply Chain, Marketing or Sales, Infrastructure, Technology or R&D

Revenue model

1. Plasma donation compensation payments: KEDPLASMA compensates individual plasma donors for each qualified plasma donation. Compensation varies by center and donation frequency. The primary revenue stream for the company is the collection of plasma which is processed by parent company Kedrion Biopharma into plasma-derived therapies (clotting factors, albumin, immunoglobulins) for treating rare diseases, distributed globally.
2. KEDLeague reward redemptions: Donors earn KEDPoints per donation, milestone achievements, birthdays, and anniversaries. Points are redeemed for e-gift cards, Express Passes, and tier-level perks. This loyalty program drives donor retention and frequency.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

Core offering

KEDPlasma operates a network of more than 70 company-owned plasma donation centers across 20+ U.S. states where healthy individual donors give source and specialty plasma in exchange for monetary compensation. Collected plasma is supplied to parent Kedrion Biopharma, which fractionates it into plasma-derived therapies (albumin, clotting factors, immunoglobulins) for treating rare and serious diseases. The collection operation is supported by the KEDPLASMA Donor App, KEDExpress pre-screening, and the KEDLeague tiered loyalty rewards program.

Product overview

KEDPLASMA operates as a plasma collection network offering a unified service platform centered on plasma donation services at over 70 centers across the United States. The portfolio includes the KEDPLASMA Donor App (mobile companion for appointment management, health tracking, and earnings planning), KEDExpress (digital pre-screening questionnaires), KEDLeague (tiered loyalty and rewards program with point redemption for gift cards), and 10 Specialty Plasma Donation Programs targeting specific antibody profiles. Plasma collected is processed through Kedrion's fractionation facilities into plasma-derived therapies. The company was established in 2004 and became part of Kedrion Biopharma, expanding in 2022 through the acquisition of BPL Plasma's 29 collection centers.

Differentiator

Problem solved

Functional benefit

Products and services

• Plasma Donation Services Core service: collection of high-quality source plasma from individual donors at 70+ company-operated donation centers across 20+ U.S. states. Plasma is supplied to parent Kedrion Biopharma for fractionation into plasma-derived therapies (albumin, clotting factors, immunoglobulins) used to treat rare and serious diseases.
• KEDPLASMA Donor App iOS and Android mobile application enabling donors to prepare for donations, view vitals (blood pressure, hematocrit, protein, pulse, weight), monitor donation history, plan monthly earnings, and manage KEDLeague loyalty rewards. Designed for individual plasma donors to streamline their donation experience and maximize compensation.
• KEDExpress Digital pre-screening service that lets donors complete required health history questionnaires on a private device before arriving at a donation center. Generates a QR code enabling fast check-in and saves approximately 10 minutes off total donation time, with priority access to the center floor.
• KEDLeague Loyalty Rewards Program (formerly KEDREWARDS) Loyalty program where plasma donors earn KEDPoints per qualified donation, milestone achievements, birthdays, and anniversaries. Points are redeemable for e-gift cards (Amazon, Walmart, AMC, Burger King, McDonald's, Target, BP) and Express Passes. Tier upgrades unlock bonus points, priority notifications, and exclusive promotions; firefighters, military, police, and students earn additional bonus KEDPoints.
• Specialty Plasma Donation Programs Collection of specialty hyperimmune plasma from donors with targeted antibodies or blood types, used to manufacture specific plasma-derived therapies for conditions including hemolytic disease of the newborn, rabies exposure, tetanus, anthrax, smallpox (strategic national stockpile), hepatitis B, CMV, and varicella zoster. Specialty donors receive additional compensation for immunizations and ongoing donations.

Quantifiable outcome

• Plasma replenishes in the body within 24-48 hours, enabling donors to give twice in a 7-day period (up to ~100 donations per year)
• +4 more outcomes

Named customers6 records

Segments4 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Four partnerships are on record, tiered minor and core.

• Stough Development CorporationminorImplementation/ SI/ Consulting Partner · 30 October 2023Stough Development Corporation is partnered with KEDPLASMA on a comprehensive nationwide facility remodeling initiative. Stough, a third-generation family business specializing in medical, office, and retail property development, is handling significant upgrades to the interior and exterior of plasma collection facilities including modernized aesthetics, improved accessibility, and state-of-the-art amenities while consolidating all BPL Plasma centers under the KEDPLASMA brand. Stough has worked in the plasma industry for over 60 years and has remodeled or developed over 70 plasma centers.
• Bio Products Laboratory (BPL) / BPL PlasmacoreStrategic or Co-development Partner · 1 January 2022UK-based Bio Products Laboratory's BPL Plasma division joined the KEDPLASMA community following Kedrion Biopharma's 2022 partnership with BPL. BPL Plasma had been a global leader in plasma collection for more than 25 years. The combination added 29 BPL plasma collection centers to KEDPLASMA's existing network, creating a combined footprint of 70+ centers across 20+ states. Plasma collected by BPL centers continues to be processed into lifesaving therapies for patients worldwide.
• Haemonetics CorporationcoreTechnology or IntegrationHaemonetics Corporation provides the donor identification system software used at KEDPLASMA plasma donation centers. The system uses a finger scan to capture a unique series of characters for secure donor authentication and verification at each visit. Donors' finger scan data is disclosed to and stored by Haemonetics, retained for up to 3 years, and not otherwise disclosed by KEDPLASMA to any other party.
• Kedrion Biopharma (Parent Company)coreStrategic or Co-development PartnerKEDPLASMA is a Kedrion Biopharma company. Kedrion is an international biopharma company that produces and distributes plasma-derived medicinal products (37 products) for treating severe and rare diseases, disorders, and conditions (Hemophilia, Immunodeficiencies) in over 100 countries. KEDPLASMA collects and procures high-quality plasma through its U.S. center network for processing by Kedrion's fractionation plants in Melville/New York, Bolognana/Italy, and Gödöllő/Hungary.

Scale indicators8 records

Recent moves8 records

Expansion highlights6 records

Direct peers

• CSL Plasma: One of the world's largest plasma collection networks, operated by CSL Behring (a global biotherapeutics company). CSL Plasma operates hundreds of U.S. centers and is the most direct competitor to KEDPlasma in paid source plasma collection, with similar donor compensation, specialty programs, and digital infrastructure.
• BioLife Plasma Services: Operated by Takeda Pharmaceutical (post-Shire acquisition), BioLife is a major U.S. plasma collection network competing directly with KEDPlasma. BioLife operates 200+ centers with similar donor compensation, app-based scheduling, and loyalty rewards programs.
• Grifols Plasma: Grifols operates one of the largest vertically integrated plasma collection-to-fractionation-to-therapeutics platforms globally. Its U.S. plasma centers compete head-to-head with KEDPlasma for donors and offer similar compensation and digital tools, with the added advantage of Grifols' downstream manufacturing scale.
• Octapharma Plasma: Owned by Octapharma AG (a Switzerland-based plasma therapeutics manufacturer), Octapharma Plasma operates 180+ U.S. donation centers and is a direct competitor with similar specialty programs, donor compensation structures, and loyalty rewards.
• B Positive Plasma: U.S.-focused plasma collection network explicitly named alongside KEDPlasma and BioLife in industry reporting as a major U.S. paid plasma collector. Comparable center footprint and donor compensation model.

Emerging players

• ADMA Biologics: U.S. commercial biopharma company focused on immune globulin therapies derived from source plasma. ADMA operates its own plasma collection centers (ADMA BioCenters) and is comparable as an emerging integrated collector-fractionator with emphasis on specialty immune globulin products.

Others

• Kedrion Biopharma: Parent company of KEDPlasma and a global biotherapeutics company fractionating plasma into 37 products distributed in 100+ countries. While not a competitor, Kedrion is the sole offtaker of KEDPlasma's plasma and is comparable as a vertically integrated plasma therapeutics peer.
• Haemonetics Corporation: Global provider of blood and plasma component management solutions, including the donor identification/biometric authentication system used by KEDPlasma centers. Haemonetics is a technology and equipment supplier rather than a collector, but is comparable as an infrastructure provider in the plasma collection value chain.

Broad incumbents

• Vitalant: One of the largest nonprofit blood and plasma collection organizations in the U.S. While Vitalant focuses primarily on whole blood and recovered plasma for transfusion (not paid source plasma), it is a meaningful peer in the broader U.S. plasma and blood collection infrastructure.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xx.com/KEDPLASMAUSA
• YouTubeyoutube.com/channel/UCaQdYH-RofeTtMd2zV-DnvA/featured
• Facebookfacebook.com/KEDPLASMAUSA
• LinkedInlinkedin.com/company/kedrion-us
• Instagraminstagram.com/kedplasmausa

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about KEDPlasma